Disease Landscape and Forecast 인사이트

In 2013, global sales of ethical oncology drugs exceeded $92 million, and sales are expected to exceed $120 million in 2020, far more than the drug revenues of any other therapy area. Thus,…

With approximately two-thirds of peripheral arterial disease (PAD) patients being asymptomatic, drug treatment for PAD patients focuses largely on the symptomatic patients who have either…

The TreatmentTrends: Rheumatoid Arthritis 2014 (EU) report explores the treatment dynamics among more than 200 French, German, Italian, Spanish, and UK rheumatologists through comprehensive primary…

The type 2 diabetes (T2D) therapy market in Latin America (LatAm) presents a large commercial opportunity to drug manufacturers. The prevalence of T2D in LatAm is high and is expected to increase,…

Psoriatic arthritis (PsA) is a disease hallmarked by psoriatic skin lesions and erosive joint damage that remains poorly understood, underdiagnosed, and undertreated. Nevertheless, tumor necrosis-…

In 2013, painful diabetic neuropathy (PDN) affected more than 3.4 million people in the United States. Similar to postherpetic neuralgia, PDN has also served—and continues to serve—as a gateway…

Gram-negative infections (GNIs) comprise a large portion of hospital-treated infections (HTIs), which represent a high-value segment of the antibacterial market given the severity of these…

Diabetic retinopathy (DR) is characterized by progressive damage to the blood vessels in the retina of a diabetic patient, from which fluid may leak causing the macula to swell. Swelling of the…

Muscular dystrophy (MD) is associated with degeneration and weakness of affected muscles that vary with the type of dystrophy. Dystrophies are characterized by common histological features such as…

The emergence of digital resources in the healthcare system has changed the healthcare experience for U.S. consumers. Online health, consumers’ use of digital resources for health research and…

The European type 2 diabetes market is contending with the convergence of innovative pharmaceutical offerings, such as Johnson & Johnson’s Invokana, AstraZeneca’s Xigduo, and Takeda’s Vipidia…

This three-wave LaunchTrends report series will track the post-launch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment of chronic obstructive pulmonary disease (…